Literature DB >> 26514175

Radiopeptides for Imaging and Therapy: A Radiant Future.

Kristell L S Chatalic1, Dik J Kwekkeboom2, Marion de Jong3.   

Abstract

Radiopeptides are powerful tools for diagnostic imaging and radionuclide therapy of various diseases. Since the introduction of the first radiopeptide into the clinical setting to diagnose neuroendocrine tumors about 25 y ago, many advances have been made in the field. This short review highlights novel strategies to improve the application of radiopeptides for imaging and therapy.
© 2015 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Entities:  

Keywords:  developments; imaging; perspectives; radionuclide therapy; radiopeptides

Mesh:

Substances:

Year:  2015        PMID: 26514175     DOI: 10.2967/jnumed.115.161158

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  15 in total

Review 1.  Peptide-based imaging agents for cancer detection.

Authors:  Xiaolian Sun; Yesen Li; Ting Liu; Zijing Li; Xianzhong Zhang; Xiaoyuan Chen
Journal:  Adv Drug Deliv Rev       Date:  2016-06-18       Impact factor: 15.470

Review 2.  Molecular imaging in neuroendocrine tumors: recent advances, controversies, unresolved issues, and roles in management.

Authors:  Tetsuhide Ito; Robert T Jensen
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2017-02       Impact factor: 3.243

Review 3.  PET imaging in patients with meningioma-report of the RANO/PET Group.

Authors:  Norbert Galldiks; Nathalie L Albert; Michael Sommerauer; Anca L Grosu; Ute Ganswindt; Ian Law; Matthias Preusser; Emilie Le Rhun; Michael A Vogelbaum; Gelareh Zadeh; Frédéric Dhermain; Michael Weller; Karl-Josef Langen; Jörg C Tonn
Journal:  Neuro Oncol       Date:  2017-11-29       Impact factor: 12.300

Review 4.  Molecular imaging to guide systemic cancer therapy: Illustrative examples of PET imaging cancer biomarkers.

Authors:  Austin R Pantel; David A Mankoff
Journal:  Cancer Lett       Date:  2016-05-16       Impact factor: 8.679

5.  The Effects of an Albumin Binding Moiety on the Targeting and Pharmacokinetics of an Integrin αvβ6-Selective Peptide Labeled with Aluminum [18F]Fluoride.

Authors:  Sven H Hausner; Nadine Bauer; Ryan A Davis; Tanushree Ganguly; Sarah Y C Tang; Julie L Sutcliffe
Journal:  Mol Imaging Biol       Date:  2020-12       Impact factor: 3.488

Review 6.  Use of PET Imaging in Neuro-Oncological Surgery.

Authors:  Adrien Holzgreve; Nathalie L Albert; Norbert Galldiks; Bogdana Suchorska
Journal:  Cancers (Basel)       Date:  2021-04-26       Impact factor: 6.639

7.  Necrosis binding of Ac-Lys0(IRDye800CW)-Tyr3-octreotate: a consequence from cyanine-labeling of small molecules.

Authors:  Marcus C M Stroet; Bianca M Dijkstra; Sebastiaan E Dulfer; Schelto Kruijff; Wilfred F A den Dunnen; Frank A E Kruyt; Rob J M Groen; Yann Seimbille; Kranthi M Panth; Laura Mezzanotte; Clemens W G M Lowik; Marion de Jong
Journal:  EJNMMI Res       Date:  2021-05-10       Impact factor: 3.138

8.  Hybrid Imaging Labels: Providing the Link Between Mass Spectrometry-Based Molecular Pathology and Theranostics.

Authors:  Tessa Buckle; Steffen van der Wal; Stijn J M van Malderen; Larissa Müller; Joeri Kuil; Vincent van Unen; Ruud J B Peters; Margaretha E M van Bemmel; Liam A McDonnell; Aldrik H Velders; Frits Koning; Frank Vanhaeke; Fijs W B van Leeuwen
Journal:  Theranostics       Date:  2017-01-12       Impact factor: 11.556

9.  NeoBOMB1, a GRPR-Antagonist for Breast Cancer Theragnostics: First Results of a Preclinical Study with [67Ga]NeoBOMB1 in T-47D Cells and Tumor-Bearing Mice.

Authors:  Aikaterini Kaloudi; Emmanouil Lymperis; Athina Giarika; Simone Dalm; Francesca Orlandi; Donato Barbato; Mattia Tedesco; Theodosia Maina; Marion de Jong; Berthold A Nock
Journal:  Molecules       Date:  2017-11-11       Impact factor: 4.411

10.  Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist 177 Lu-DOTAGA-PEG2 -RM26.

Authors:  Bogdan Mitran; Sara S Rinne; Mark W Konijnenberg; Theodosia Maina; Berthold A Nock; Mohamed Altai; Anzhelika Vorobyeva; Mats Larhed; Vladimir Tolmachev; Marion de Jong; Ulrika Rosenström; Anna Orlova
Journal:  Int J Cancer       Date:  2019-05-23       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.